NCT05119777已完成4 期
Prospective, Open Label, Post Marketing Study of the Safety and Effectiveness of HArmonyCa Injectable Gel for Mid-face Soft Tissue Augmentation
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 140
- 试验地点
- 4
- 主要终点
- Responder status of achieving ≥ 1-grade improvement from baseline on Mid Face Volume Deficit Scale (MFVDS) based on EI's (Evaluating Investigator) live assessment at Month 1
研究概览
简要总结
Prospective, open label, post marketing study of the safety and effectiveness of HArmonyCa injectable gel for mid-face soft tissue augmentation
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 or older at the time of signing the ICF
- •In general good health
- •Participant seeking soft tissue augmentation in the mid face
- •Has moderate or severe mid face volume deficit (Grade 5, 4, or 3 on the MFVDS) for each cheek on EI (Evaluating Investigator) live assessment (both cheeks must qualify but do not need to have the same score)
- •Each cheek is amenable to achieving at least a 1-point improvement on the MFVDS with study intervention in the judgment of the EI (Evaluating Investigator)/TI (Treating Investigator)
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
- •Written informed consent from the participant has been obtained prior to any study-related procedures
- •Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
- •Able, as assessed by the EI, and willing to follow study instructions (including compliance with the safety diary) and likely to complete all required study visits
- •Fluent and literate in French
排除标准
- •HArmonyCa is contraindicated:
- •in patients with a known sensitivity to any of the product components.
- •in patients suffering from skin disease or abnormal skin conditions.
- •in patients suffering from an infection or inflammation (either acute or chronic) at or near the treatment site.
- •in patients susceptible to keloid formation, hypertrophic scarring, or developing inflammatory skin conditions.
- •in patients with impaired wound healing due to systemic disorders, medicinal drugs, or unhealthy or poorly-vascularized tissue.
- •in patients suffering from prolonged bleeding or tissue healing due to medical conditions or medicinal drugs.
- •in patients with a history of anaphylactic reactions and/or multiple severe allergies.
- •in patients with a known sensitivity to steroids, or who are contraindicated to be treated with steroids.
- •for injection into the glabellar or periocular areas.
- •for injection into the lips and perioral region.
- •for injection into regions containing foreign bodies.
- •in patients presenting with herpes.
- •in patients with autoimmune diseases.
- •for injection into blood vessels and to highly vascularized areas.
- •for injection into the epidermis or superficial dermis.
- •in breastfeeding or pregnant women.
- •in patients below the age of
- •Has experienced trauma to the face within 6 months before enrollment or has residual deficiencies, deformities, or scarring
- •History of anaphylaxis or allergy to HA products, or Streptococcal protein
- •Fat injection or permanent facial implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face
- •Semi-permanent soft-tissue filler treatment (eg, CaHA, poly-L-lactic acid) in the face within 36 months before enrollment
- •Temporary dermal filler injections in the face within 24 months before enrollment
- •Botulinum toxin treatment in the cheek area (including crow's feet, depressor anguli oris, jawline, platysma, etc.) within 6 months before enrollment
- •Mesotherapy or cosmetic facial procedures in the face within 6 months before enrollment. Examples of mesotherapy or cosmetic facial procedures are face-lift, laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures.
- •Changes in use of over-the-counter or prescription oral or topical, anti-wrinkle products in the face within 30 days before enrollment or planned changes during the study. Participants are not eligible for this study if they have begun using any new over-the-counter or prescription oral or topical, anti-wrinkle products in the face within 30 days before enrollment or are planning to begin using such products during the study. Participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study.
- •Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)
- •Has received LASIK surgery or other surgical intervention on the eye within 3 months prior to enrollment or is planning such a procedure
- •Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study
- •Has tattoos, piercings, facial hair, or scars in the face that would interfere with the visualization of the face for the effectiveness assessment
- •Has undergone a dental procedure within 6 weeks before treatment or plans to undergo a dental procedure (other than prophylaxis or dental fillings) during the course of the study
- •Females who are pregnant, planning a pregnancy, or nursing.
- •TI's discretion based on participant's safety and/or study integrity. The participant has a condition or is in a situation that, in the TI's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study.
- •Directly or indirectly involved in the conduct and administration of this study. Directly or indirectly involved in the conduct and administration of this study as an investigator, sub-investigator, study coordinator, or other study staff member; employee of the sponsor; first degree family member, significant other, or relative residing with one of the above persons involved directly or indirectly in the study; or enrolled in the study at another clinical site.
结局指标
主要结局
Responder status of achieving ≥ 1-grade improvement from baseline on Mid Face Volume Deficit Scale (MFVDS) based on EI's (Evaluating Investigator) live assessment at Month 1
时间窗: 1 Month
The MFVDS is a validated, 6-point scale with grades of severe (5), significant (4), moderate (3), mild (2), minimal (1), and none (0)
次要结局
- Responder status of achieving improved or much improved on GAIS based on participant assessment at Month 1 visit(1 Month)
- Change from baseline on FACE-Q Satisfaction with Cheeks specific questionnaire at Month 1 visit(1 Month)
- Responder status of achieving improved or much improved on Global Aesthetic Improvement Scale (GAIS) based on EI live assessment at Month 1 visit(1 Month)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 CapsuleHealthyNCT01548157Hanmi Pharmaceutical Company Limited28
已完成
1 期
Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male VolunteersHealthyNCT01869985Hanmi Pharmaceutical Company Limited30
撤回
2 期
Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in ChildrenPainNCT02542098Purdue Pharma LP
撤回
1 期
Gene Therapy for the Treatment of Chronic Stable AnginaMyocardial IschemiaNCT01002495Helixmith Co., Ltd.
终止
2 期
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)Warm Autoimmune Hemolytic Anemia (wAIHA)NCT04661033Sanofi8